CN108743633B - Application of combination of radix Actinidiae chinensis total triterpenes and radix Actinidiae chinensis polysaccharide in preparing medicine for preventing and treating digestive system tumor and lung cancer - Google Patents

Application of combination of radix Actinidiae chinensis total triterpenes and radix Actinidiae chinensis polysaccharide in preparing medicine for preventing and treating digestive system tumor and lung cancer Download PDF

Info

Publication number
CN108743633B
CN108743633B CN201810618401.1A CN201810618401A CN108743633B CN 108743633 B CN108743633 B CN 108743633B CN 201810618401 A CN201810618401 A CN 201810618401A CN 108743633 B CN108743633 B CN 108743633B
Authority
CN
China
Prior art keywords
group
root
polysaccharide
actinidia
actinidia root
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810618401.1A
Other languages
Chinese (zh)
Other versions
CN108743633A (en
Inventor
申力
张光霁
徐楚韵
陈喆
楼招欢
张广顺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INSTITUTE OF BASIC THEORY CACMS
Zhejiang Chinese Medicine University ZCMU
Original Assignee
INSTITUTE OF BASIC THEORY CACMS
Zhejiang Chinese Medicine University ZCMU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSTITUTE OF BASIC THEORY CACMS, Zhejiang Chinese Medicine University ZCMU filed Critical INSTITUTE OF BASIC THEORY CACMS
Priority to CN201810618401.1A priority Critical patent/CN108743633B/en
Publication of CN108743633A publication Critical patent/CN108743633A/en
Application granted granted Critical
Publication of CN108743633B publication Critical patent/CN108743633B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses an application of a combination of a Chinese actinidia root total triterpenoid and Chinese actinidia root polysaccharide in preparation of a medicine for preventing and treating digestive system tumors and lung cancer. In the application, the concentration of the actinidia chinensis planch root polysaccharide is 0.5mg/mL, and the concentration ratio of the actinidia chinensis planch root polysaccharide to the actinidia chinensis planch root total triterpenoid is 1 mg: (0.0165-0.1747) mol; the total triterpenes of radix Actinidiae chinensis comprises ursolic acid and oleanolic acid. According to the application, the Chinese actinidia root polysaccharide and the Chinese actinidia root total triterpenoid are mixed according to a certain concentration ratio, so that the obtained Chinese actinidia root active ingredient composition has a better tumor proliferation inhibition effect than that of the single Chinese actinidia root polysaccharide or the single Chinese actinidia root total triterpenoid, and the Chinese actinidia root polysaccharide and the Chinese actinidia root total triterpenoid have a synergistic effect under a certain proportion.

Description

Application of combination of radix Actinidiae chinensis total triterpenes and radix Actinidiae chinensis polysaccharide in preparing medicine for preventing and treating digestive system tumor and lung cancer
Technical Field
The invention belongs to the field of antitumor drugs, and particularly relates to an application of a combination of a actinidia root total triterpenoid and actinidia root polysaccharide in preparation of a medicine for preventing and treating digestive system tumors and lung cancer.
Background
The understanding of traditional Chinese medicine on tumors can be traced back to the age of Yizhou, and the disease name of the tumors is mentioned in the early ancient ruin oracle texts in Yizhou. Meanwhile, the tumor and the aimed treatment method are already included in the swelling and ulcer diseases recorded in Zhou Li recorded as early as 2000 years ago, and the symptoms that the ulcer is treated by five toxins, five qi nourishments and five medicines are treated by five medicines are mentioned. Meanwhile, the traditional Chinese medicine considers that the occurrence, development and change of tumors are the result of the change of the relationship between vital qi and pathogenic factors. On the basis of the deficiency of healthy qi and the imbalance of yin, yang, qi and blood of the zang-fu organs, the invasion of exogenous pathogenic factors and the pathological products of phlegm, dampness, qi and blood stasis formed inside the body are combined.
The understanding of the etiology and pathogenesis of gastric cancer in all ages mainly includes: stomach failing to descend and liver failing to disperse and purge; anxiety, anger and emotional disorder; internal injury due to overstrain and spleen and stomach injury due to chronic diseases can cause disorder of qi, blood and channels of viscera, and finally, heat toxin, blood stasis, phlegm coagulation and retardation are caused to combine with stomach to form tumor. The accumulation of toxic heat is the main pathogenesis of the disease, so the medicine with the efficacy of clearing heat and removing toxicity is selected for development and treatment.
The Chinese medicine Actinidia root is the root of Actinidia Chinensis Planch of Actinidia Chinensis (Actinidia Chinensis) of Actinidiaceae, has the effects of clearing heat, invigorating stomach and promoting diuresis, and is recorded in Hebei Chinese herbal medicine, namely, the Chinese medicine Actinidia root has an anticancer effect and particularly has a good curative effect on gastrointestinal cancer. The Chinese actinidia root has the effects of clearing heat and removing toxicity, softening hardness and reducing swelling, and is used for developing and treating the pathogenesis of heat-toxin accumulation of the gastric cancer. The synergy of multiple components and multiple targets is the advantages and characteristics of the traditional Chinese medicine effect.
For example, chinese patent application No. CN200510126430.9 discloses a actinidia root extract and its anticancer use, wherein the actinidia root extract is obtained by reflux extraction of actinidia root with ethanol, mainly the more polar and medium polar substances in actinidia root, wherein the more polar actinidia root extract with a concentration of 500 μ g/ml has the best growth inhibition effect on tumor cell lines to be tested, the inhibition rate on liver cancer is 22.3 ± 7.67%, the inhibition rate on stomach cancer is 20.47 ± 0.13%, and the inhibition rate on cervical cancer is 21.63 ± 2.56%.
Although the components of the Chinese actinidia root extract are relatively single by improving the extraction method in the technology, the specific components of the Chinese actinidia root extract are still unclear, although researches on the components of the Chinese actinidia root extract by scholars at home and abroad in recent years find that the active components of the Chinese actinidia root total triterpenes (such as ursolic acid, oleanolic acid and the like) and the Chinese actinidia root polysaccharide and the like have the effect of inhibiting the proliferation of tumor cells, the composition of each active component in the natural Chinese actinidia root extract is not very clear, the proportion of the clear active components in the natural Chinese actinidia root composition is not the optimal proportion, and the growth inhibition effect on each tumor cell is still to be further improved.
Disclosure of Invention
The invention aims to provide an active ingredient composition of Chinese actinidia root, which can remarkably improve the growth inhibition effect of the active ingredients of the Chinese actinidia root on various tumor cells.
In order to achieve the above purpose, the technical solution of the present application is as follows:
a composition containing active ingredients of radix Actinidiae chinensis is prepared by mixing radix Actinidiae chinensis polysaccharide and radix Actinidiae chinensis total triterpenes, wherein the ratio of the radix Actinidiae chinensis polysaccharide to the radix Actinidiae chinensis total triterpenes is 1 mg: (0.0165-0.1747) mol, wherein the actinidia root total triterpenoid is composed of ursolic acid and oleanolic acid.
According to the application, the Chinese actinidia root polysaccharide and the Chinese actinidia root total triterpenoid are mixed according to a certain concentration ratio, so that the obtained Chinese actinidia root active ingredient composition has a better tumor proliferation inhibition effect than that of the single Chinese actinidia root polysaccharide or the single Chinese actinidia root total triterpenoid, and the Chinese actinidia root polysaccharide and the Chinese actinidia root total triterpenoid have a synergistic effect under a certain proportion.
Based on the above, the application provides an application of the combination of the Chinese actinidia root total triterpenoid and the Chinese actinidia root polysaccharide in preparing a medicine for preventing and treating the tumor of the digestive system, wherein in the application, the concentration of the Chinese actinidia root polysaccharide is 0.5mg/mL, and the ratio of the Chinese actinidia root polysaccharide to the Chinese actinidia root total triterpenoid is 1 mg: (0.0165-0.1747) mol.
Preferably, the actinidia root total triterpenoid is composed of ursolic acid and oleanolic acid.
The composition of ursolic acid and oleanolic acid in the total triterpenoids of radix Actinidiae chinensis is different for different tumor cells. The applicant finds that when the Chinese actinidia root active ingredient composition achieves 50% inhibition rate on BGC-823 gastric cancer cells, the concentration ratio of ursolic acid to oleanolic acid in the Chinese actinidia root total triterpenoid is (3.743-12.983) 1; when the MKN7 gastric cancer cells reach 50% inhibition rate, the concentration ratio of ursolic acid to oleanolic acid in the actinidia root total triterpenoid is (2.18-2.32): 1; when the SGC7901 gastric cancer cells reach 50% inhibition rate, the concentration ratio of ursolic acid to oleanolic acid in the actinidia root total triterpenoid is (1.67-3.71): 1;
when the PANC-1 pancreatic cancer cells reach 50 percent of inhibition rate, the concentration ratio of ursolic acid to oleanolic acid in the total triterpenoids of the Chinese actinidia root is (0.354-0.654): 1;
when the HCT116 colon cancer cells reach 50% inhibition rate, the concentration ratio of ursolic acid to oleanolic acid in the actinidia root total triterpenoid is (3.539-4.319) 1;
when the inhibition rate of Hep-G2 liver cancer cells reaches 50%, the concentration ratio of ursolic acid to oleanolic acid in the total triterpenoids of the actinidia root is (1.65-2.03): 1.
The application also provides an application of the combination of the Chinese actinidia root total triterpenoid and the Chinese actinidia root polysaccharide in the preparation of a lung cancer prevention and treatment medicine, wherein in the application, the concentration of the Chinese actinidia root polysaccharide is 0.5mg/mL, and the ratio of the Chinese actinidia root polysaccharide to the Chinese actinidia root total triterpenoid is 1 mg: (0.0173-0.0191) mol;
the total triterpenes of radix Actinidiae chinensis comprises ursolic acid and oleanolic acid.
The applicant finds that when the H1975 lung cancer cells reach 50% inhibition rate, the concentration ratio of ursolic acid to oleanolic acid in the total triterpenoids of the actinidia root is (0.384-0.524): 1.
The application also provides a medicine for preventing and treating the tumors of the digestive system, which comprises at least one of a medicine for preventing and treating gastric cancer, a medicine for preventing and treating pancreatic cancer, a medicine for preventing and treating colon cancer and a medicine for preventing and treating liver cancer, and is prepared from the composition of the active ingredients of the Chinese actinidia root.
The application also provides a lung cancer prevention and treatment medicine which is prepared from the Chinese actinidia root active ingredient composition.
Compared with the prior art, the invention has the beneficial effects that:
according to the application, the actinidia chinensis root polysaccharide and the actinidia chinensis root total triterpenoid are mixed according to a certain concentration ratio, different ursolic acid and oleanolic acid ratios are set for specific tumor cells, the obtained actinidia chinensis root active ingredient composition has a better tumor proliferation inhibition effect than that of the single actinidia chinensis root polysaccharide or the single actinidia chinensis root total triterpenoid, and the actinidia chinensis root polysaccharide and the actinidia chinensis root total triterpenoid have a synergistic effect under a certain ratio. The application provides further support for the research and development of clinical antitumor drugs, can better improve the efficiency of antitumor treatment, can further exert the characteristic advantages of traditional Chinese medicine antitumor treatment, and improves the quality of life of patients.
Detailed Description
The technical means of the present invention will be described in further detail below with reference to specific embodiments.
Example 1 inhibitory Effect of composition of active ingredient of Actinidia chinensis planch on BGC-823 gastric cancer cell
1. Cell culture
BGC-823 gastric cancer cell line was purchased from Shanghai institute of sciences cell Bank.
(1) Cell resuscitation
Taking out the freezing tube from liquid nitrogen, putting the tube into a water bath kettle at 37 ℃ for unfreezing, and quickly shaking to accelerate cell thawing. After the liquid is completely melted (about 1-1.5 minutes), alcohol is sprayed and the liquid is put into a clean bench.
② sucking the cell suspension into a 15ml centrifuge tube, simultaneously adding 1ml culture solution into the centrifuge tube, and then placing the centrifuge tube into a centrifuge for centrifugation (800-.
Thirdly, abandoning the supernatant, adding 1ml of culture solution, shaking the centrifuge tube, blowing the cells with a pipette gun to suspend the cells, and then putting the cell suspension into a place of 25cm24ml of culture medium was added to the flask, and the flask was gently shaken to uniformly distribute the cells.
Fourthly, the cell types and the dates are marked outside the culture bottle, the human is cultured, and finally, the culture bottle is placed with 5 percent CO at the temperature of 37 DEG C2Culturing in an incubator.
(2) Subculturing of cells
The culture was decanted and washed once with PBS.
② adding 1-2ml of pancreatin (0.05% of Trypsin-EDTA) according to the growth condition of the cells, preferably completely covering the cell layer with the pancreatin, and putting the cell layer into an incubator at 37 ℃ for digestion for 5 min.
Thirdly, observing under a microscope, when the cells are round but not completely shed, adding 2-3ml of culture solution with serum, stopping digestion, and then blowing and beating the cells by using a pipette gun to ensure that the cells completely shed and become single cells.
Fourthly, the cell suspension is collected and then centrifuged (800 plus 1000rpm,5min), and after centrifugation is finishedDiscarding supernatant, adding 1ml culture solution to blow out cells, mixing well, adding cell suspension to 25cm24ml of culture medium was added to the flask, and the flask was gently shaken to distribute the cells uniformly.
Fifthly, placing the culture bottle after the treatment into a culture bottle with the temperature of 37 ℃ and the CO content of 5 percent2Culturing in an incubator.
2. MTT method for detecting inhibition effect of composition of active ingredients of Chinese actinidia root on BGC-823 cell proliferation
Taking stomach cancer cell strain BGC-823 in logarithmic growth phase, digesting and counting, and counting at 6 × 103Each cell is inoculated in 100 mul/well of 96-well cell culture plate, after 24h of culture and cell adherence, the cells are divided into a blank group, a negative group, five administration groups and six control groups, each experiment group is provided with 5 multiple wells, wherein the administration group is repeated for 3 times (5 multiple wells are arranged for each time) to obtain three groups of results of 'inhibition rate 1', 'inhibition rate 2' and 'inhibition rate 3', and the control group is repeated for two times (5 multiple wells are arranged for each time) to obtain two groups of results of 'inhibition rate 1' and 'inhibition rate 2'. As in table 1.
TABLE 1 settings for each of the drug administration groups and the control group
Experimental group Pharmaceutical composition
Administration set (1) Crude polysaccharide 0.5mg/ml + ursolic acid: oleanolic acid 1:1
Medicine administration group 2 Crude polysaccharide 0.5mg/ml + ursolic acid: oleanolic acid 2:1
Medicine administration group Crude polysaccharide 0.5mg/ml + ursolic acid: oleanolic acid 4:1
Medicine administration group IV Crude polysaccharide 0.5mg/ml + ursolic acid: oleanolic acid 8:1
Administration group (c) Crude polysaccharide 0.5mg/ml + ursolic acid: oleanolic acid 16:1
Comparison group (1) Crude polysaccharide 0.5mg/ml
Comparison group 2 Ursolic acid: oleanolic acid 1:1
Control group c Ursolic acid: oleanolic acid 2:1
Comparison group iv Ursolic acid: oleanolic acid 4:1
Control group (c) Ursolic acid: oleanolic acid 8:1
Control group (c) Ursolic acid: oleanolic acid 16:1
Note: (1) in the table, the concentration of oleanolic acid was 6.25. mu. mol/l, as follows;
(2) in the table, crude polysaccharide was given by the college of medicine of Zhejiang university of traditional Chinese medicine, and ursolic acid and oleanolic acid were purchased from Dowmaste Biotech Co.
After the drug acts on tumor cells for 24 hours, adding MTT with the concentration of 5mg/ml, keeping incubating for 4 hours at 37 ℃ with 10 mul of MTT in each hole, fully forming crystals, discarding supernatant, adding 150 mul of DMSO, placing on a shaking bed, oscillating for 10min at low speed to fully dissolve the crystals, measuring the optical density OD value of each hole at 490nm by using an enzyme labeling instrument, averaging the OD values of all parallel holes, and calculating the inhibition ratio:
the inhibition ratio (%) was 1- (administration group OD value mean-blank OD value mean)/(negative group OD value mean-blank OD value mean).
And calculating IC based on the calculated inhibition ratio50(inhibition ratio is 50%) the concentration ratio of ursolic acid and oleanolic acid, and IC is compared50And judging the effectiveness of each matching combination and determining the optimal matching range.
The calculation results are shown in Table 2.
TABLE 2 inhibition rate and IC of each experimental group on BGC-823 gastric cancer cell50Value comparison
Experimental group Inhibition ratio 1 Inhibition ratio 2 Inhibition ratio 3
Administration set (1) 1.560％ 33.074％ 33.646％
Medicine administration group 2 38.233％ 49.775％ 35.677％
Medicine administration group 48.984％ 49.549％ 57.729％
Medicine administration group IV 47.424％ 48.504％ 59.738％
Administration group (c) 37.382％ 53.873％ 59.891％
Administration group IC50The concentration ratio of ursolic acid to oleanolic acid 4.255 6.765 14.070
Comparison group (1) 50.952％ 59.603％
Comparison group 2 23.542％ 20.520％
Control group c 26.374％ 34.510％
Comparison group iv 25.930％ 38.588％
Control group (c) 25.148％ 37.574％
Control group (c) 37.342％ 41.801％
Control group IC50The concentration ratio of ursolic acid to oleanolic acid 635.403 36.324
Example 2 inhibitory Effect of Actinidia chinensis planch root active ingredient composition on MKN1 gastric cancer cells
MKN1 gastric cancer cell line purchased from Shanghai academy of sciences cell bank, the test procedure is the same as example 1, and the inhibition rate and IC5 of MKN1 gastric cancer cells are tested by each test group0The values are shown in Table 3.
TABLE 3 inhibition rate and IC of each experimental group on MKN1 gastric cancer cells50Value comparison
Experimental group Inhibition ratio 1 Inhibition ratio 2 Inhibition ratio 3
Administration set (1) 8.93％ 8.64％ 14.75％
Medicine administration group 2 13.81％ 14.41％ 14.79％
Medicine administration group 18.89％ 13.60％ 19.03％
Medicine administration group IV 66.48％ 16.40％ 23.98％
Administration group (c) 85.41％ 71.44％ 83.05％
Administration group IC50The concentration ratio of ursolic acid to oleanolic acid 6.19 13.30 9.66
Comparison group (1) 16.90％ 39.69％
Comparison group 2 26.25％ 41.37％
Control group c 23.16％ 41.25％
Comparison group iv 42.46％ 36.60％
Control group (c) 95.98％ 45.47％
Control group (c) 99.41％ 93.83％
Concentration ratio of ursolic acid and oleanolic acid in control group IC50 3.018 3.573
Example 3 inhibitory Effect of Actinidia chinensis planch root active ingredient composition on MKN7 gastric cancer cells
MKN7 gastric cancer cell line purchased from Shanghai academy of sciences cell bank, the test procedure is the same as example 1, and the inhibition rate and IC of MKN7 gastric cancer cell are respectively tested50The values are shown in Table 4.
TABLE 4 inhibition rate and IC of each experimental group on MKN7 gastric cancer cells50Value comparison
Experimental group Inhibition ratio 1 Inhibition ratio 2 Inhibition ratio 3
Administration set (1) 48.49％ 39.20％ 30.44％
Medicine administration group 2 54.52％ 39.83％ 48.31％
Medicine administration group 50.71％ 48.47％ 52.19％
Medicine administration group IV 66.44％ 65.97％ 67.16％
Administration group (c) 69.17％ 89.83％ 96.03％
Concentration ratio of ursolic acid and oleanolic acid when group IC50 is administered 1.44 2.73 2.59
Comparison group (1) 10.56％ 6.26％
Comparison group 2 4.26％ 23.11％
Control group c 3.45％ 37.30％
Comparison group iv 21.62％ 45.98％
Control group (c) 27.30％ 58.82％
Control group (c) 98.85％ 96.01％
Concentration ratio of ursolic acid and oleanolic acid in control group IC50 7.937 3.608
Example 4 inhibitory Effect of composition of active ingredient of Actinidia chinensis planch root on SGC7901 gastric cancer cell
SGC7901 gastric cancer cell line was purchased from Shanghai department of sciences cell Bank, the test procedure was the same as in example 1, and each experimental group was paired with SGInhibition rate and IC of C7901 gastric cancer cells50The values are shown in Table 5.
TABLE 5 inhibition and IC of SGC7901 gastric cancer cells by each experimental group50Value comparison
Experimental group Inhibition ratio 1 Inhibition ratio 2 Inhibition ratio 3
Administration set (1) 45.95％ 36.16％ 25.88％
Medicine administration group 2 54.53％ 51.77％ 49.39％
Medicine administration group 64.81％ 43.58％ 50.71％
Medicine administration group IV 71.61％ 56.72％ 55.78％
Administration of drugsGroup (c) 77.72％ 83.49％ 71.25％
Concentration ratio of ursolic acid and oleanolic acid when group IC50 is administered 1.35 2.92 3.82
Comparison group (1) 47.07％ 46.07％
Comparison group 2 45.20％ 41.31％
Control group c 38.90％ 50.17％
Comparison group iv 45.84％ 51.37％
Control group (c) 52.79％ 54.13％
Control group (c) 81.54％ 71.28％
Control group IC50The concentration ratio of ursolic acid to oleanolic acid 3.177 2.680
Example 5 inhibitory Effect of Actinidia chinensis planch root active ingredient composition on SW1990 pancreatic cancer cells
SW1990 pancreatic cancer cell line purchased from Shanghai institute of sciences cell bank, the test procedure was the same as example 1, and each experimental group had the inhibition rate and IC of SW1990 pancreatic cancer cell50The values are shown in Table 6.
TABLE 6 inhibition and IC of SW1990 pancreatic cancer cells by each experimental group50Value comparison
Experimental group Inhibition ratio 1 Inhibition ratio 2 Inhibition ratio 3
Administration set (1) 65.17％ 57.88％ 58.19％
Medicine administration group 2 65.33％ 58.25％ 56.12％
Medicine administration group 55.75％ 64.33％ 60.80％
Medicine administration group IV 71.38％ 69.21％ 83.46％
Administration group (c) 91.79％ 92.54％ 91.49％
Concentration ratio of ursolic acid and oleanolic acid when group IC50 is administered 0.49 0.91 0.911
Comparison group (1) 53.95％ 55.26％
Comparison group 2 97.38％ 97.82％
Control group c 65.89％ 97.78％
Comparison group iv 81.01％ 99.56％
Control group (c) 98.71％ 98.87％
Control group (c) 99.27％ 97.58％
Control group IC50The concentration ratio of ursolic acid to oleanolic acid 0.078 0
Example 6 inhibitory Effect of composition of active ingredients of Actinidia chinensis planch root on PANC-1 pancreatic cancer cells
PANC-1 pancreatic cancer cell line was purchased from Shanghai institute of Chinese sciences cell bank, the test procedure was the same as example 1, and each experimental group had the inhibition rate and IC of PANC-1 pancreatic cancer cell50The values are shown in Table 7.
TABLE 7 inhibition and IC of PANC-1 pancreatic cancer cells by each experimental group50Value comparison
Experimental group Inhibition ratio 1 Inhibition ratio 2 Inhibition ratio 3
Administration set (1) 56.51％ 61.14％ 63.48％
Medicine administration group 2 58.66％ 69.28％ 69.85％
Medicine administration group 68.90％ 75.19％ 71.78％
Medicine administration group IV 77.75％ 81.97％ 84.47％
Administration group (c) 81.85％ 85.87％ 88.37％
Administration group IC50The concentration ratio of ursolic acid to oleanolic acid 0.721 0.385 0.408
Comparison group (1) 20.515％ 25.576％
Comparison group 2 20.188％ 24.720％
Control group c 23.651％ 24.644％
Comparison group iv 51.884％ 33.936％
Control group (c) 50.662％ 53.259％
Control group (c) 67.795％ 53.335％
Control group IC50The concentration ratio of ursolic acid to oleanolic acid 6.107 10.434
Example 7 inhibitory Effect of Actinidia chinensis planch root active ingredient composition on HCT116 Colon cancer cells
HCT116 Colon cancer cell line purchased from Shanghai institute of sciences cell bank, the test procedure was the same as example 1, and the inhibition rate and IC of HCT116 Colon cancer cells were determined for each experimental group50The values are shown in Table 8.
TABLE 8 inhibition and IC of HCT116 Colon cancer cells by each experimental group50Value comparison
Experimental group Inhibition ratio 1 Inhibition ratio 2 Inhibition ratio 3
Administration set (1) 43.41％ 40.19％ 36.25％
Medicine administration group 2 46.74％ 41.52％ 26.70％
Medicine administration group 45.87％ 45.19％ 40.30％
Medicine administration group IV 49.28％ 48.14％ 54.09％
Administration group (c) 71.33％ 70.61％ 91.89％
Administration group IC50The concentration ratio of ursolic acid to oleanolic acid 3.41 4.38 3.99
Comparison group (1) 66.36％ 71.47％
Comparison group 2 14.52％ 35.38％
Control group c 53.62％ 41.54％
Comparison group iv 64.42％ 54.55％
Control group (c) 77.05％ 61.92％
Control group (c) 79.74％ 74.46％
Control group IC50The concentration ratio of ursolic acid to oleanolic acid 2.733 3.087
Example 8 inhibitory Effect of composition of active ingredient of Actinidia chinensis planch on Hep-G2 liver cancer cell
Hep-G2 hepatoma cell line was purchased from Shanghai institute of Chinese academy of sciences cell bank, the test procedure was the same as example 1, and the inhibition rate and IC of Hep-G2 hepatoma cells were determined by each experimental group50The values are shown in Table 9.
TABLE 9 inhibition rate and IC of Hep-G2 liver cancer cell by each experimental group50Value comparison
Experimental group Inhibition ratio 1 Inhibition ratio 2 Inhibition ratio 3
Administration set (1) 42.93％ 52.34％ 22.37％
Medicine administration group 2 52.43％ 52.45％ 46.96％
Medicine administration group 58.25％ 56.77％ 60.09％
Medicine administration group IV 81.00％ 82.92％ 87.05％
Administration group (c) 92.36％ 91.15％ 96.96％
Administration group IC50The concentration ratio of ursolic acid to oleanolic acid 1.73 1.391 2.393
Comparison group (1) 31.60％ 30.25％
Comparison group 2 16.33％ 24.33％
Control group c 33.17％ 28.80％
Comparison group iv 54.67％ 28.37％
Control group (c) 59.97％ 33.93％
Control group (c) 68.77％ 49.17％
Control group IC50The concentration ratio of ursolic acid to oleanolic acid 4.842 29.857
Example 9 inhibitory Effect of composition of active ingredients of Actinidia chinensis planch on H1975 Lung cancer cells
H1975 Lung cancer cell line was purchased from Shanghai department of sciences cell Bank, the test procedure was the same as example 1, and the inhibition ratio and IC of H1975 lung cancer cell were determined by each experimental group50The values are shown in Table 10.
TABLE 10 inhibition and IC of H1975 Lung cancer cells by each experimental group50Value comparison
Experimental group Inhibition ratio 1 Inhibition ratio 2 Inhibition ratio 3
Administration set (1) 64.78％ 63.71％ 59.21％
Medicine administration group 2 64.87％ 66.25％ 61.80％
Medicine administration group 66.43％ 66.96％ 65.48％
Medicine administration group IV 70.00％ 77.77％ 75.35％
Administration group (c) 91.88％ 86.29％ 82.19％
Administration group IC50The concentration ratio of ursolic acid to oleanolic acid 0.432 0.373 0.558
Comparison group (1) 60.21％ 58.51％
Comparison group 2 70.78％ 68.52％
Control group c 70.51％ 69.73％
Comparison group iv 99.45％ 73.13％
Control group (c) 99.77％ 71.91％
Control group (c) 98.20％ 95.16％
Control group IC50The concentration ratio of ursolic acid to oleanolic acid 0.685 0.284
By combining the data in tables 2 to 10, the IC of each cell line was obtained for the administration group and the control group50The mean values of the concentration ratios of ursolic acid and oleanolic acid (obtained from inhibition ratios 1, 2, and 3) and the standard deviations of the mean values are shown in table 11.
TABLE 11
Cell line Cell source Mean IC of the groups administered50Value of Mean IC of control group50Value of
BGC823 Gastric cancer cell 8.363±4.62 335.863±423.612
MKN1 Gastric cancer cell 9.72±2.9 3.295±0.392
MKN7 Gastric cancer cell 2.25±0.07 5.772±3.061
SGC-7901 Gastric cancer cell 2.69±1.02 2.928±0.351
SW1990 Pancreatic cancer cell 0.77±0.19 0.039±0.055
PANC-1 Pancreatic cancer cell 0.504±0.15 8.2705±3.0596
HCT116 Colon cancer cells 3.929±0.39 2.91±0.250
Hep-G2 Liver cancer cell 1.84±0.19 17.349±17.688
H1975 Lung cancer cell 0.454±0.07 0.484±0.283

Claims (2)

1. The application of the combination of the actinidia root triterpenoid and the actinidia root polysaccharide in the preparation of the pancreatic cancer prevention and treatment medicine is characterized in that the concentration of the actinidia root polysaccharide is 0.5mg/mL, the actinidia root triterpenoid is composed of ursolic acid and oleanolic acid, the molar ratio of the ursolic acid to the oleanolic acid is 16:1, and the concentration of the oleanolic acid is 6.25 mu mol/L.
2. A pancreatic cancer prevention and treatment drug, characterized by being prepared from the actinidia root total triterpenoid compound and actinidia root polysaccharide of claim 1.
CN201810618401.1A 2018-06-15 2018-06-15 Application of combination of radix Actinidiae chinensis total triterpenes and radix Actinidiae chinensis polysaccharide in preparing medicine for preventing and treating digestive system tumor and lung cancer Active CN108743633B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810618401.1A CN108743633B (en) 2018-06-15 2018-06-15 Application of combination of radix Actinidiae chinensis total triterpenes and radix Actinidiae chinensis polysaccharide in preparing medicine for preventing and treating digestive system tumor and lung cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810618401.1A CN108743633B (en) 2018-06-15 2018-06-15 Application of combination of radix Actinidiae chinensis total triterpenes and radix Actinidiae chinensis polysaccharide in preparing medicine for preventing and treating digestive system tumor and lung cancer

Publications (2)

Publication Number Publication Date
CN108743633A CN108743633A (en) 2018-11-06
CN108743633B true CN108743633B (en) 2021-05-18

Family

ID=64022683

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810618401.1A Active CN108743633B (en) 2018-06-15 2018-06-15 Application of combination of radix Actinidiae chinensis total triterpenes and radix Actinidiae chinensis polysaccharide in preparing medicine for preventing and treating digestive system tumor and lung cancer

Country Status (1)

Country Link
CN (1) CN108743633B (en)

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"藤梨根总三萜化合物通过下调N-Cadherin、Snail抑制BGC-823胃癌细胞侵袭的体内外实验研究;张广顺等;《中华中医药杂志》;20160430;第31卷(第4期);第1188-1192页，摘要 *
中华猕猴桃根化学成分及其生物活性研究;张琳;《中国优秀博硕士学位论文全文数据库（硕士）医药卫生辑》;20160415(第04期);第E057-27页，摘要 *
中药藤梨根提取物体外抗肿瘤活性部位的筛选;何国浓等;《中华中医药杂志》;20170630;第32卷(第6期);第2863-2865页，尤其是摘要，第2864页右栏最后1段 *
熊果酸和齐墩果酸的抗消化系肿瘤作用;张明发等;《上海医药》;20111231;第32卷(第12期);第606-609、611页，尤其是第607页左栏最后1段 *
猕猴桃根多糖对人胃癌 SGC-7901 细胞增殖凋亡及 p-p38 表达的影响;宋文瑛等;《中国中西医结合杂志》;20140331;第34卷(第3期);第329-333页，摘要 *
藤梨根多糖的分离纯化与活性研究;张昕;《中国优秀博硕士学位论文全文数据库（硕士）工程科技辑》;20100815(第08期);第B016-131页，摘要 *
齐墩果酸对顺铂耐药胃癌 S G C - 7901细胞增殖的影响及其机制研究;李鸿梅等;《中国药理学通报》;20091031;第25卷(第10期);第1334-1337页，尤其是第1334页左栏摘要，右栏第3段 *

Also Published As

Publication number Publication date
CN108743633A (en) 2018-11-06

Similar Documents

Publication Publication Date Title
WO2015030283A1 (en) Composition for preventing and treating cancer-related fatigue, containing processed ginseng powder or processed ginseng extract having increased ginsenoside constituent
CN104398526B (en) The application of triptolide and Celastrol in antineoplastic is prepared
CN110051677A (en) A kind of application of Gardenoside in terms of alleviating glucocorticoid side effect
CN107823211A (en) Application of the gucosamine in preparing ionising radiation and causing induced lung injury protective agents
CN115428949A (en) Probiotic traditional Chinese medicine composition with weight-losing function and preparation method thereof
WO2010028075A1 (en) Herbal composition for treating cancer
CN106798755B (en) Probiotic composition with function of conditioning hyperplasia of mammary glands and application thereof
CN108743633B (en) Application of combination of radix Actinidiae chinensis total triterpenes and radix Actinidiae chinensis polysaccharide in preparing medicine for preventing and treating digestive system tumor and lung cancer
CN116948901A (en) Application of Weissella antrum D-2 extracellular polysaccharide in inhibiting colon cancer cells
CN113413402B (en) Application of plum blossom extract in preparation of medicine for treating helicobacter pylori infection disease
CN107007594A (en) Vitamin C and oxaliplatin are combined the effect in antitumor
CN102309483B (en) New application of berberine ion pair compound in tumor resistance
WO2018058863A1 (en) Use of polyether compounds
CN108403941B (en) Traditional Chinese medicine composition for treating pancreatic cancer and preparation method and application thereof
CN112618569A (en) Medicine for treating urothelial cancer
CN102008495B (en) Application of berberine and doxorubicine mixed preparation in preparation of medicament against doxorubicine cardiac dysfunction or tumor
CN103877126B (en) Knurl lid intends the pharmaceutical usage of shelf fungus and the pharmaceutical composition for the treatment of tumour
CN104887690B (en) Application of the chonglou saponin in antitumor drug is prepared
CN110496225A (en) Stephanine and autophagy inhibitor are combined the application in preparation treatment liver-cancer medicine
CN103142584B (en) Application of polysubstituted 5-hydroxypyrrolidone compounds in preparation of antitumor medicines
CN105878253A (en) Medical application of corosolic acid
CN116407600B (en) Traditional Chinese medicine compound for treating lung cancer and application of traditional Chinese medicine compound for treating lung nodule
CN102440987A (en) Drug compound of apigenin, apigenin-like derivants, artemisinin and artemisinin-like derivants and application thereof
CN101716171A (en) Application of scutellarin extract in preparation medicaments for preventing and treating pulmonary fibrosis
Zhao et al. Inhibitory Effect of Semen Litchi Drug Serum on the Proliferation of Human Hepatoma HepG2 Cells and Expression of VEGF and MMP-9

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant